Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-HER2 dual-specific antibody and application thereof

A bispecific antibody, HCDR2 technology, applied in the field of biomedicine, can solve problems such as poor stability, poor binding activity, and precipitation

Pending Publication Date: 2020-08-11
SHANGHAI BAO PHARM CO LTD
View PDF9 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, prior art (CN105829347A; CN105820251A; CN105980409A) antibodies have the characteristics of poor antigen binding activity, or poor stability and easy to form precipitates, and stability is a necessary condition for antibody druggability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-HER2 dual-specific antibody and application thereof
  • Anti-HER2 dual-specific antibody and application thereof
  • Anti-HER2 dual-specific antibody and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Example 1: Construction and expression of bispecific antibodies against different epitopes of human HER2

[0055] DNA fragments encoding trastuzumab heavy chain (including knob structure), pertuzumab heavy chain (including hole structure) and trastuzumab light chain (SEQ ID NO: 2) were synthesized from the whole gene and cloned into The expression vector constructed in our laboratory consists of the following components:

[0056] 1) glutamine synthetase gene, as a selection marker; or neomycin resistance gene, as a heavy chain selection marker,

[0057] 2) Origin of replication: ori,

[0058] 3) origin of replication from vector pUC18, which allows replication of this plasmid in E. coli,

[0059] 4) a β-lactamase gene which confers ampicillin resistance in Escherichia coli,

[0060] 5) Immediate early enhancer and promoter from human cytomegalovirus,

[0061] 6) a human 1-immunoglobulin polyadenylation ("poly A") signal sequence, and

[0062] As described above, im...

Embodiment 2

[0067] Example 2: Determination of the affinity between anti-human HER2 different epitope bispecific antibodies and HER2

[0068] Biacore T200 was used to determine the affinity of single-target HER2 antibodies trastuzumab, pertuzumab, and HER2 bispecific antibody KJ015w to three forms of HER2 antigen.

[0069] First, the Anti-Human Fc (AHC) antibody was coupled to the CM5 chip, and then the antibody IgG (2 μg / ml) to be tested was captured by AHC, and three kinds of antigen molecules of different concentrations flowed over the chip surface captured IgG, The binding activity of HER2 antibody to different concentrations of antigens was detected, and the obtained data were fitted according to Biacore T200 analysis software to obtain exact kinetic constants. The comparison results are shown in Table 2.

[0070] Table 2: Affinity test results of antibody KJ015w and three forms of HER2 antigen

[0071]

[0072] Trastuzumab, Pertuzumab and the bispecific anti-HER2 antibody KJ015w...

Embodiment 3

[0073]Example 3: Detection of anti-human HER2 different epitope bispecific antibody cell proliferation inhibitory activity

[0074] MDA-MB-175 cell culture flasks were placed in a 37°C, 5% carbon dioxide constant temperature incubator for static culture, and the color of the medium and cell confluence were observed every day, and the cell doubling time was recorded. Cells were subcultured every 2-4 days. When the cells are about 80% full layer, the seed plate is digested. Discard the medium, wash once with PBS, and add 0.25% trypsin (Gibco) for digestion. Collect the cells into a centrifuge tube by pipetting and centrifuge at 500 g for 3 min. Discard the supernatant, add complete medium to resuspend the cells, and take 100 μL of the cell suspension for counting. Adjust the cell density to 1 × 10 with medium containing 2% FBS 5 cells / mL, 100 μL per well was spread into a 96-well plate.

[0075] Dilute the drug to be tested with medium containing 2% FBS, first dilute the dr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-HER2 dual-specific antibody. The antibody comprises a first protein functional area and a second protein functional area used for identifying an extracellular domain IIand an extracellular domain IV of HER2 respectively, wherein the first protein functional area comprises a first heavy chain and a light chain, and the second protein functional area comprises a second heavy chain and a light chain. The sequences of the first heavy chain, the second heavy chain and the light chains are shown in the description. Pharmaceutical compositions comprising the dual-specific antibody and uses thereof are also disclosed. The dual-specific antibody and the pharmaceutical composition containing the same can be used for treatment of cancers.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to an anti-HER2 bispecific antibody and its application. Background technique [0002] HER2 is a 185 kDa cell surface receptor tyrosine kinase and a member of the epidermal growth factor receptor (EGFR) family, which includes four different receptors: EGFR / ErbB-1, HER2 / ErbB-2, HER3 / ErbB-3, and HER4 / ErbB-4. The four members of the EGFR family form homodimers and heterodimers, with HER2 being the preferred and strongest dimeric partner of the other ErbB receptors (Graus-Porta et al., Embo J 1997; 16 : 1647-1655; Tao et al., J Cell Sci 2008; 121: 3207-3217). HER2 can be activated by overexpression or by heterodimerization with other ErbBs that can be activated by ligand binding (Riese and Stern, Bioessays 1998; 20:41-48). For HER2, no ligand has been identified. HER2 activation leads to receptor phosphorylation, which triggers downstream signaling cascades through multiple signaling path...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/32C12N15/13A61K39/395A61K47/68A61P35/00
CPCC07K16/32A61K47/6851A61P35/00C07K2317/52C07K2317/56C07K2317/565C07K2317/515C07K2317/51C07K2317/31A61K2039/505C07K2317/24C07K2317/73C07K2317/732C07K2317/76C07K2317/77C07K2317/92C07K2317/34C07K2317/94A61K39/395C07K14/82C07K16/46
Inventor 王征徐云霞
Owner SHANGHAI BAO PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com